Dose-specific Moderna coronavirus vaccine trials to start in July
The final study of mRNA-1273, on 30,000 people, will be conducted with the US National Institute of Allergy and Infectious Diseases
New York — Moderna has said it has selected a dose for a final-stage clinical trial of its coronavirus vaccine that should begin in July, as the company moves ahead rapidly with its innovative approach to trying to prevent Covid-19.
The final study, which will include 30,000 people, will be conducted in collaboration with the National Institute of Allergy and Infectious Diseases in the US. Its primary goal will be to show the vaccine prevents people from developing symptoms of Covid-19, Moderna said in a statement. A secondary goal will be to show the vaccine keeps people from getting severe cases that require hospitalisation...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.